Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01453101 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
A Phase 2 study of Multiple Myeloma, sponsored by Hackensack Meridian Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT01453101: Completed Phase 2 study of Multiple Myeloma, sponsored by Hackensack Meridian Health.
NCT01453101 is a Phase 2 study of Multiple Myeloma that has completed, run by Hackensack Meridian Health. The registered enrollment target is 54 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01453101, a Phase 2 study of Multiple Myeloma, has completed, sponsored by Hackensack Meridian Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
The hypothesis for this study is that the regimen consisting of fludarabine, melphalan and bortezomib improves the progression free survival and the response rate compared to historical controls of fludarabine and melphalan alone.
Conditions Studied
Interventions
- DRUG Fludarabine monophosphate, melphalan, Bortezomib
Study Locations (1)
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2010-06-09 |
| Est. Completion | 2020-06-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01453101
The ClinicalTrials.gov registry entry for NCT01453101 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Fludarabine monophosphate, melphalan, Bortezomib is the first listed.
NCT01453101 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT01453101 about?
NCT01453101 is a clinical study titled "Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma". The hypothesis for this study is that the regimen consisting of fludarabine, melphalan and bortezomib improves the progression free survival and the response rate compared to historical controls of fludarabine and melphalan alone.
What is the current status of trial NCT01453101?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2010-06-09. Estimated completion is 2020-06-11.
What conditions does trial NCT01453101 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT01453101?
The interventions under investigation include: Fludarabine monophosphate, melphalan, Bortezomib (DRUG).
Who is sponsoring clinical trial NCT01453101?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01453101 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.